Table 1.

Patient Characteristics at Baseline by Treatment Arm: Intent-to-Treat Population

Characteristic	Treatment Arm
	OBL-FC (n = 120)		FC (n = 121)
	No.	%	No.	%
Sex
Male	89	74	89	74
Race/ethnicity
White	105	88	109	90
Black	6	5	7	6
Hispanic	8	7	4	3
Other	1	1	1	1
Age, years
Median	63		63
Range	35-86		42-82
≥ 65	53	44	52	43
≥ 75	17	14	10	8
ECOG performance status
0	41	34	38	31
≥ 1	78	65	80	66
Unknown	1	1	2	2
Rai stage
≤ 2	66	55	59	49
3-4	54	45	61	50
Unknown	0	0	1	1
Median time from diagnosis, months	70		58
No. of prior regimens
1-2	60	50	63	52
≥ 3	60	50	58	48
Fludarabine sensitivity
Relapsed	51	43	50	41
Refractory	69	58	71	59
Response to last therapy, months
> 6	54	45	52	43
≤ 6	66	55	69	57
β2 microglobulin*
< 4	57	48	58	48
≥ 4	52	43	47	39
Serum LDH level†
< ULN range	63	53	63	52
≥ ULN range	53	44	52	43
Platelet count, × 103/μL
< 100,000	43	36	43	36
≥ 100,000	77	64	78	64

Abbreviations: OBL-FC, oblimersen plus fludarabine/cyclophosphamide; FC, fludarabine/cyclophosphamide; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ULN, upper limit of normal.

^*Not available for 11 patients in the OBL-FC group and 16 patients in the FC group.

^†Not available for four patients in the OBL-FC group and six patients in the FC group.